Anti-idiotype melanoma vaccine - Biogen Idec
Alternative Names: MELIMMUNE; MELIMMUNE-1; MELIMMUNE-2Latest Information Update: 10 Aug 2006
Price :
$50 *
At a glance
- Originator Biogen Idec
- Class Cancer vaccines; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 10 Aug 2006 Discontinued - Phase-I/II for Malignant melanoma in USA (unspecified route)
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 20 Jun 2002 This compound is still in active development